SFRP2 and ovarian cancer: Finally, we used an online resource31 (https://kmplot.com/analysis/) to determine whether the ECM signature that associates with M0 macrophages associated with overall survival (OS), where we found a significant decrease in the median OS of ovarian cancer patients (OS = 28.25 months) compared to the low expression cohort (OS = 45.63 months; Supplementary Fig. 7A), with a greater hazard ratio (HR = 1.56) than the expression of any gene alone, except COL11A1 or SFRP2 (HR = 1.78 and HR = 1.66, respectively, Supplementary Fig. 8).